Cargando…

Neutralization and enhancement of trans infection by erythrocyte-bound HIV with antibodies and complement

Detalles Bibliográficos
Autores principales:	Beck, Z, Matyas, GR, Polonis, VR, Alving, CR
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442076/ http://dx.doi.org/10.1186/1742-4690-9-S2-P49

Ejemplares similares

Cross-clade neutralization of HIV-1 by a monoclonal antibody obtained by immunization with liposomes containing lipid A and a synthetic MPER peptide
por: Matyas, GR, et al.
Publicado: (2012)

P05-04. Neutralizing antibodies induced by immunization with liposomal gp41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes
por: Matyas, GR, et al.
Publicado: (2009)

P12-08. Membrane-specific antibodies that simultaneously bind to gp41 of HIV-1 and membrane lipid epitopes are induced by immunization with liposomes
por: Beck, Z, et al.
Publicado: (2009)

P04-22. Multispecific monoclonal antibodies bind to primary human macrophages and induce the production of protective chemokines, MIP-1α and MIP-1β
por: Weaver, KL, et al.
Publicado: (2009)

P04-19. Analysis of the binding of multiple clades of HIV-1 by a modified virus capture assay
por: Peachman, K, et al.
Publicado: (2009)

Soluble and bacteriophage T4 displayed gp41 mutant proteins as HIV-1 vaccine candidates
por: Gao, G, et al.
Publicado: (2012)

The impact of differences in viral entry and trafficking on the mechanism of HIV-1 neutralization
por: Cincotta, CD Macedo, et al.
Publicado: (2012)

Human Erythrocytes Selectively Bind and Enrich Infectious HIV-1 Virions
por: Beck, Zoltan, et al.
Publicado: (2009)

P04-23. HIV-1 neutralization is impacted by the PBMC donor used for both virus growth and target cells, and the effects are neutralization reagent-specific
por: Wieczorek, L, et al.
Publicado: (2009)

Platelets and Erythrocyte-Bound Platelets Bind Infectious HIV-1 in Plasma of Chronically Infected Patients
por: Beck, Zoltan, et al.
Publicado: (2013)

P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays
por: Brown, BK, et al.
Publicado: (2009)

P04-28. Breadth and magnitude of neutralizing antibody responses in subjects infected with HIV-1 subtype D or recombinants in Rakai district, Uganda
por: Eller, L, et al.
Publicado: (2009)

Systemic administration of a broadly-neutralizing IgG antibody to generate HIV-neutralization responses in breast milk
por: Fouda, GG, et al.
Publicado: (2012)

Antigenicity and immunogenicity of a novel, acute HIV-1 Tanzanian subtype C gp145 envelope protein for clinical development
por: Polonis, V, et al.
Publicado: (2012)

P05-09. 4e10 epitope-scaffolds mimic the antibody-bound epitope conformation and block neutralization by sera from rare HIV+ individuals
por: Ban, YA, et al.
Publicado: (2009)

Detection of antibodies to the α4β7 integrin binding site on HIV-1 gp120 V2 loop using a novel cell adhesion assay
por: Rao, M, et al.
Publicado: (2012)

Postnatally-transmitted HIV-1 variants are efficient at dendritic cell trans-infection and sensitive to autologous and heterologous neutralization
por: Fouda, GG, et al.
Publicado: (2012)

In silico prediction of the neutralization range of human anti-HIV monoclonal antibodies
por: Shmelkov, E, et al.
Publicado: (2012)

Neutralizing anti-HIV antibodies develop in a humanized mouse model of HIV-1 infection
por: Seung, E, et al.
Publicado: (2012)

Isolation of broadly neutralizing HIV-1 antibodies from high-throughput single B cell culture
por: Longo, NS, et al.
Publicado: (2012)

Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus
por: Mayr, LM, et al.
Publicado: (2012)

P19-41. Full-length IMC expressing Renilla luciferase for neutralization assay using PBMC
por: Chenine, A, et al.
Publicado: (2009)

P19-03. Molecular mechanisms for enhancing the antigenicity of the carbohydrate epitope of the broadly neutralizing anti-HIV-1 antibody 2G12
por: Fulton, Z, et al.
Publicado: (2009)

P05-03. The use of immune complexes to enhance antibody responses against neutralizing epitopes on HIV envelope
por: Hioe, CE, et al.
Publicado: (2009)

Neutralizing and non-neutralizing antibody responses in HIV-1 subtype C chronically infected patients with divergent rates of disease progression
por: Archary, D, et al.
Publicado: (2012)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Recognition and penetration of the HIV-1 Env glycan shield by potent broadly neutralizing antibodies
por: Julien, J, et al.
Publicado: (2012)

Novel vomputational methods for predicting epitopes of potent and broadly neutralizing HIV-1 antibodies
por: Evans, MC, et al.
Publicado: (2012)

P04-04. The specific phospholipid binding and neutralizing activities of the anti-HIV antibody 4E10 are separable
por: Xu, H, et al.
Publicado: (2009)

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
por: Joachim, A, et al.
Publicado: (2012)

Optimization and validation of the HIV-1 neutralizing antibody assay in A3R5 cells
por: Sarzotti-Kelsoe, M, et al.
Publicado: (2012)

P04-29. HIV-1 neutralizing antibodies inhibit plasmacytoid dendritic cells infection
por: Lederle, A, et al.
Publicado: (2009)

Broad and potent neutralization of HIV-1 by human-llama fusion antibodies derived from immunized llamas
por: McCoy, LE, et al.
Publicado: (2012)

P04-15. Prevalence of broadly neutralizing antibody responses during acute/early HIV infection
por: Mikell, I, et al.
Publicado: (2009)

LYSIS OF ERYTHROCYTES BY COMPLEMENT IN THE ABSENCE OF ANTIBODY
por: Götze, Otto, et al.
Publicado: (1970)

Erythrocyte binding activity of Plasmodium vivax tryptophan rich antigens is inhibited by patients’ antibodies
por: Tyagi, Rupesh K, et al.
Publicado: (2012)

P04-53 LB. Potent and broad HIV-specific neutralizing antibodies in infants are not associated with prevention of mother to infant HIV transmission
por: Lynch, J, et al.
Publicado: (2009)

P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group
por: Scarlatti, G, et al.
Publicado: (2009)

Construction of SHIVs expressing quaternary neutralization epitopes in Env and mimicking the neutralization phenotype of typical HIV-1 isolates
por: Theis, JF, et al.
Publicado: (2012)

The breadth of maternal HIV-1 specific neutralizing antibodies is not associated with a lower risk of mother-to-infant transmission
por: Chaillon, A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_u2hvt7dbm8cb87f9giagu0oitc